Last reviewed · How we verify
SOMATROPIN
At a glance
| Generic name | SOMATROPIN |
|---|---|
| Drug class | Recombinant Human Growth Hormone [EPC] |
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
Common side effects
- Peripheral swelling
- Arthralgia
- Hypothyroidism
- Elevated HbA1c
- Eosinophilia
- Hematoma
- Headache
- Hypertriglyceridemia
- Leg pain
- Injection site reactions/rashes
- Lipoatrophy
- Peripheral edema
Serious adverse events
- Benign intracranial hypertension
- Central precocious puberty
- Aggravation of preexisting scoliosis
- Transient hyperglycemia
Key clinical trials
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance (PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOMATROPIN CI brief — competitive landscape report
- SOMATROPIN updates RSS · CI watch RSS